Related Experiment Videos
Treating irritable bowel syndrome: overview, perspective and future therapies
1Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R) Program, Mayo Clinic College of Medicine, Charlton 8-110, 200 First Street SW, Rochester, MN 55905, U.S.A. stanislav.cynthia@mayo.edu
British Journal of Pharmacology
|March 24, 2004
Summary
Developing new treatments for irritable bowel syndrome (IBS) faces challenges due to poor understanding of its mechanisms and symptoms. However, advances in clinical trials and neuroenteric science offer exciting opportunities for novel IBS therapies.
Area of Science:
- Gastroenterology
- Neurogastroenterology
- Pharmacology
Background:
- Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with complex and poorly understood mechanisms.
- Current diagnostic methods lack specificity, and non-invasive tests for identifying underlying dysfunctions are limited.
- Existing therapies offer incomplete relief for many patients.
Purpose of the Study:
- To summarize the current challenges in understanding and treating IBS.
- To highlight emerging opportunities for developing novel therapeutic strategies for IBS.
- To discuss recent advances in clinical trial design and neuroenteric science relevant to IBS.
Main Methods:
- Review of current literature on IBS pathophysiology and treatment.
- Analysis of recent advancements in clinical trial methodologies and endpoints.
- Examination of progress in neuroenteric science and its therapeutic implications.
Main Results:
- Key challenges include insufficient mechanistic understanding, symptom overlap, diagnostic difficulties, and lack of non-invasive diagnostic tools.
- Significant opportunities arise from improved clinical trial designs and relevant endpoints.
- Advances in neuroenteric science have led to new medications like alosetron and tegaserod.
Conclusions:
- Despite challenges, progress in understanding neuroenteric pathways offers promising avenues for novel IBS therapies.
- Future treatments may involve modulators of serotonergic, tachykininergic, opioid, and cannabinoid systems.
- Continued research in basic science and clinical trials is crucial for advancing IBS management.